Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : 'Likely link' between rare heart inflammation and Pfizer, Moderna vaccines -CDC advisers

06/23/2021 | 12:02pm EDT

June 23 (Reuters) - Rare cases of heart inflammation in adolescents and young adults is likely linked to vaccination with the Pfizer/BioNTech and Moderna COVID-19 shots, a group of doctors advising the U.S. Centers for Disease Control and Prevention (CDC) said in a presentation released on Wednesday.

The COVID-19 Vaccine Safety Technical (VaST) Work Group said in their report that the risk of myocarditis or pericarditis following vaccination with the mRNA-based shots in adolescents and young adults is notably higher after the second dose and in males.

The CDC said in another report that the patients with heart inflammation following vaccination generally recover from the symptoms and do well.

The Advisory Committee on Immunization Practices (ACIP) is meeting on Wednesday to assess the possibility of a link between the heart condition and the mRNA vaccines. VaST is a sub-group of ACIP.

The CDC has been investigating cases of heart inflammation mainly in young men for several months. The Israeli health ministry earlier this month said it saw a possible link between such cases and Pfizer's COVID-19 vaccine.

The CDC earlier this month said it was still evaluating the risk from the condition and did not confirm a causal relationship between the vaccines and the heart issue.

The agency, however, said a higher-than-expected number of young men have experienced heart inflammation after their second dose of the mRNA COVID-19 shots, with more than half the cases reported in people between the ages of 12 and 24.

Dr. Tom Shimabukuro, deputy director of the CDC's Immunization Safety Office, said in a presentation that data from one of the agency's safety monitoring systems - Vaccine Safety Datalink (VSD) – suggests a rate of 12.6 cases per million in the three weeks after the second shot in 12- to 39-year-olds.

ACIP will discuss the benefits of the mRNA vaccines versus the potential risk to adolescents and young adults from the heart condition, according to the agency's agenda. https://www.cdc.gov/vaccines/acip/meetings/downloads/agenda-archive/agenda-2021-06-23-508.pdf

Although health officials in Israel have determined that there is likely a link between vaccination and the heart inflammation, concerns about the more infectious Delta coronavirus variant have prompted the country to urge 12-to 15-year olds get vaccinated.

Pfizer, whose vaccine has been authorized for use in Americans as young as 12, previously said it had not observed a higher rate of heart inflammation than would normally be expected in the general population.

Moderna had said it could not identify a causal association with the heart inflammation cases and its vaccine.

Over 138 million Americans have so far been fully vaccinated with one of the two mRNA vaccines, according to CDC data as of Monday. (Reporting by Michael Erman in New Jersey and Manojna Maddipatla in Bengaluru; Editing by Bill Berkrot)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -0.45% 413.76 Delayed Quote.301.12%
PFIZER, INC. -0.80% 44.81 Delayed Quote.22.77%
All news about MODERNA, INC.
11:39aGLOBAL MARKETS LIVE : Robinhood, Bayer, MetLife, Uber, WPP...
11:05aTHE LATEST : Moderna plans booster doses to help fight virus
10:25aMODERNA : Swings to Second-Quarter Profit, Says COVID-19 Booster Shot Against De..
10:21aWall St edges higher as jobless claims fall, Robinhood weighs on Nasdaq
09:26aToday on Wall Street: Unemployment benefits claims continue to fall
09:20aSECTOR UPDATE : Health Care Stocks Mixed Premarket Thursday
08:59aMODERNA : says its COVID-19 shot 93% effective six months after second dose
08:57aMODERNA : COVID-19 vaccine tallies more than $4B in Q2 sales
08:44aMODERNA : Confirms 93% Vaccine Efficacy Six Months After Second Dose
07:53aMODERNA : Swings to Profit in Q2, Revenue Rises
More news
Financials (USD)
Sales 2021 19 117 M - -
Net income 2021 10 725 M - -
Net cash 2021 11 948 M - -
P/E ratio 2021 16,6x
Yield 2021 -
Capitalization 168 B 168 B -
EV / Sales 2021 8,18x
EV / Sales 2022 9,29x
Nbr of Employees 1 300
Free-Float 90,3%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 419,05 $
Average target price 187,80 $
Spread / Average Target -55,2%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.301.12%168 260
LONZA GROUP AG26.76%59 023
CELLTRION, INC.-24.93%32 166
SEAGEN INC.-6.81%29 694